A new drug in development just increased its chances to find its way on the shelves in pharmacies very soon. This drug, temporarily called APL-130277, is a product developed to offset « off » periods on patients with Parkinson’s disease. It’s during this period, usually a few hours following a dose, that the beneficial effects slowly disappear to gradually let in classic symptoms of the disease: slowness, loss of dexterity, stiffness, difficulty to move and walk.
The Food and Drug Agency, in the USA, has decided to accelerate the approval process of the drug in development APL-130277, which is a very good news. This product has already passed with success various clinical stages and is currently in the third stage of clinical trials. During this stage, therapeutic essays are conducted on hundreds or thousands of patients. The goal is to evaluate the efficiency of the drug and its tolerance. It is important to mention that the development of a new drug for a condition such as Parkinson’s disease goes through many stages which can take years. There is no question that this is good news for patients living with Parkinson’s disease if the tests are a success and the various decision-making bodies approve its marketing.
Cynapsus pharmaceutical company